India & India — Central Drugs Standard Control Organisation
21 shared events · Importance 6 · Last updated Sep 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
India: India approved its first dengue vaccine, addressing a major public health challenge. The country accounts for one-third of global dengue cases, and the vaccine could reduce disease burden and healthcare strain.
India — Central Drugs Standard Control Organisation: CDSCO, under the Ministry of Health, conducted the scientific evaluation and granted marketing authorization for QDENGA, enabling its introduction in India.
Jul 20, 2026 · 93 articles
Regulatory
India: India's drug regulatory system is under the spotlight as it investigates a potentially spurious batch of a widely used vaccine. The country's high rabies burden makes vaccine safety critical.
India — Central Drugs Standard Control Organisation: The regulator flagged the batch and ordered an investigation, demonstrating vigilance. Its actions may enhance its credibility but also highlight challenges in monitoring counterfeit drugs.
Sep 04, 2026 · 7 articles
Domestic
India: India is strengthening its digital public infrastructure for health by launching several new initiatives, including Aarogya Setu 2.0, a Drug Registry, and e-Sushrut Clinic, aiming to make healthcare more integrated, accessible, and citizen-centric.
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation collaborated in the development of the Drug Registry, ensuring standardization of medicine data across India's healthcare system.
Jun 27, 2026 · 32 articles
Regulatory
India: India is the host and central actor, seeking to strengthen its global pharmaceutical hub status through regulatory cooperation and trade agreements.
India — Central Drugs Standard Control Organisation: The national drug regulatory authority that will implement the digital platform, enhancing its efficiency and transparency.
Jul 31, 2026 · 7 articles
Business
India: India's healthcare sector benefits from the availability of a new targeted cancer therapy, Tanstrive, which addresses a specific genetic alteration in various solid tumors. This improves treatment options for Indian patients.
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation provided marketing authorization for Tanstrive, enabling its launch in India and ensuring regulatory compliance for the new drug.
Jun 25, 2026 · 7 articles
Regulatory
India: India is the country where the approval was granted; the decision addresses a significant public health burden of fatty liver disease.
India — Central Drugs Standard Control Organisation: The CDSCO is the Indian regulatory body that granted the approval, enabling the expanded use of Wegovy for MASH.
Jul 17, 2026 · 13 articles
International
India: India is a co-chair of the meeting and seeks to expand trade and gain market access for pharmaceuticals. The event supports India's trade diversification goals.
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation-Brazil — Brazilian Health Regulatory Agency MoU provides a regulatory framework for pharmaceutical market access, benefiting Indian drug exports.
Aug 31, 2026 · 7 articles
Regulatory
India: The advisory applies nationwide across India's healthcare and pharmacy sectors, affecting drug sale practices and public health outcomes. It reflects ongoing regulatory attention to antimicrobial resistance and kidney disease.
India — Central Drugs Standard Control Organisation: The apex drug regulator is the primary issuer of the advisory, mandating prescription-only sales and supervised use of NSAIDs and antibiotics. Its action strengthens its regulatory stance but imposes compliance burdens on pharma and pharmacy retail.
Sep 22, 2026 · 20 articles
International
India: India reaffirmed its commitment to eliminate Hepatitis B and C as public health threats by 2030 and its drug regulator issued a new advisory on painkillers and antibiotics, shaping the domestic pharmaceutical regulatory environment.
India — Central Drugs Standard Control Organisation: It issued an advisory circular against indiscriminate use of NSAIDs and antibiotics over Chronic Kidney Disease risks, potentially curbing unregulated sales of these drugs in India.
Sep 23, 2026 · 6 articles
Tech
India: India>>> is the country where Zayn Malik>>> was discovered and developed, and where it first received regulatory approval from the India — Central Drugs Standard Control Organisation>>>.
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation>>> approved Zayn Malik>>> for import and marketing in India, providing Wockhardt>>> with a domestic market for its new antibiotic.
May 29, 2026 · 9 articles
Regulatory
India: India's regulatory framework is being tested; the case could clarify the applicability of drug laws to duty-free shops.
India — Central Drugs Standard Control Organisation: CDSCO conducted the inspection and issued the order to discontinue sales; it is enforcing drug regulations.
Jul 07, 2026 · 17 articles
Regulatory
India: India's regulatory body approved a new treatment for MASH, improving healthcare options for patients with liver disease.
India — Central Drugs Standard Control Organisation: CDSCO granted approval for the new indication, enabling Emcure to offer Poviztra for MASH treatment.
Jul 20, 2026 · 8 articles
Regulatory
India: India is the beneficiary country, with the scheme aimed at strengthening its pharma and MedTech R&D ecosystem. This could enhance India's position as a global hub for pharmaceutical innovation.
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation is referenced as the regulatory body for novel medical devices, which are a priority area under the scheme. Its approval processes will be relevant for projects seeking to commercialize innovative devices.
Aug 28, 2026 · 6 articles
Regulatory
India: The regulatory changes proposed by the Bangladesh — Ministry of Health and Family Welfare are intended to benefit the medical device industry and patients within India by improving ease of doing business and ensuring timely availability of quality medical devices.
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation is involved as the draft notification for the amendments is available on its website for stakeholder comments.
Jun 28, 2026 · 6 articles
Business
India: India gains access to its first disease-modifying Alzheimer's therapy, addressing a significant dementia burden, though adoption faces challenges.
India — Central Drugs Standard Control Organisation: CDSCO granted marketing authorisation for Leqembi, enabling its launch in India, reflecting its regulatory role.
Aug 03, 2026 · 6 articles
Business
India: Gains access to its first approved dengue vaccine through the private market from 2027, addressing a significant public health burden.
India — Central Drugs Standard Control Organisation: India's drug regulator granted marketing authorisation for QDENGA in July 2026, enabling the subsequent distribution deal.
Sep 18, 2026 · 20 articles
Regulatory
India: The advisory applies across Indian states and union territories, tightening regulation of stem cell therapy nationwide and affecting its healthcare and biotech sectors.
India — Central Drugs Standard Control Organisation: As central licensing authority it has approved two CAR-T cell therapies, NexCAR19 and Qartemi, illustrating the approved-indication pathway.
Sep 17, 2026 · 20 articles
Business
India: Included among the 120 high-incidence licensed territories; local companies secured a clinical trial waiver and await final marketing approval from the domestic regulator.
India — Central Drugs Standard Control Organisation: Its subject expert committee recommended approval of lenacapavir in India, but final marketing approval for the drug is still pending.
Sep 17, 2026 · 6 articles
Regulatory
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation alerted the India — Drugs Control Administration, Telangana, about the adulteration of Almont-Kid Syrup, playing a crucial role in identifying the issue.
Jan 10, 2026 · 6 articles
Regulatory
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation is collaborating with state regulators in India to curb malpractices in the GLP-1 drug supply chain.
Mar 24, 2026 · 11 articles
Regulatory
India — Central Drugs Standard Control Organisation: The India — Central Drugs Standard Control Organisation is responsible for strengthening manufacturing processes and avoiding compliance failures within India's pharmaceutical sector, contributing to the new regulations.
Jun 16, 2026 · 22 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and India — Central Drugs Standard Control Organisation interact across events, view sentiment trends, and discover connected entities.
Open Dashboard